guidelines:
  1: GALAD_Model_for_Hepatocellular_Carcinoma_HCC_guideline.v1
test_cases:
- id: 80 yr, F, AFP-L3 5, AFP 6,DCP 7
  input:
    1:
      gt0003|Gender: 0|local::at0005|Female|
      gt0004|Age: 80,a
      gt0005|AFP-L3: 5,%
      gt0006|AFP: 6,nanogm/ml
      gt0007|DCP: 7,nanogm/ml
  expected_output:
    1:
      gt0010|Probability of concurrent HCC in this CLD patient: 56.50,%
      gt0009|GALAD Score: 0.26
- id: 50 yr, Male, AFP-L3 5, AFP 6, DCP 7
  input:
    1:
      gt0003|Gender: 1|local::at0006|Male|
      gt0004|Age: 50,a
      gt0005|AFP-L3: 5,%
      gt0006|AFP: 6,nanogm/ml
      gt0007|DCP: 7,nanogm/ml
  expected_output:
    1:
      gt0010|Probability of concurrent HCC in this CLD patient: 31.60,%
      gt0009|GALAD Score: -0.77
- id: 80 yr, AFP-L3 10, AFP 5, DCP 6.5
  input:
    1:
      gt0003|Gender: 1|local::at0006|Male|
      gt0004|Age: 80,a
      gt0005|AFP-L3: 10,%
      gt0006|AFP: 5,nanogm/ml
      gt0007|DCP: 6.5,nanogm/ml
  expected_output:
    1:
      gt0010|Probability of concurrent HCC in this CLD patient: 87.10,%
      gt0009|GALAD Score: 1.91
- id: 80 yr, Female, AFP-L3 10, AFP 5, DCP 6.5
  input:
    1:
      gt0003|Gender: 0|local::at0005|Female|
      gt0004|Age: 80,a
      gt0005|AFP-L3: 10,%
      gt0006|AFP: 5,nanogm/ml
      gt0007|DCP: 6.5,nanogm/ml
  expected_output:
    1:
      gt0010|Probability of concurrent HCC in this CLD patient: 56.00,%
      gt0009|GALAD Score: 0.24
